Health data aggregator Validic goes bicoastal with Infometers acquisition

Featured Story

Health data aggregator Validic goes bicoastal with Infometers acquisition

July 8, 2014 12:03 pm by | 0 Comments

Validic’s first acquisition shows that data aggregators are on the rise. Health IT companies that can pull data from medical devices, wearables and mobile health apps to make remote monitoring…


Who’s got eyes on Paxil and GSK’s other drugs up for bid? Sources say Indian & U.S. pharmas

Who’s got eyes on Paxil and GSK’s other drugs up for bid? Sources say Indian & U.S. pharmas

July 22, 2014 8:57 am by | 0 Comments

LONDON/MUMBAI (Reuters) – Indian generics firm Lupin, some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older…


Pfizer acquires drug development company with 30+ injectable eye products in the works

Pfizer acquires drug development company with 30+ injectable eye products in the works

July 21, 2014 9:39 am by | 0 Comments

United States-based Pfizer has signed a contract to acquire InnoPharma, a United States-based pharmaceutical development company, it was reported on Friday. The transaction is valued at USD360m. Under the deal,…



Gentiva gets $634M buyout offer — but it’s not from Kindred

Gentiva gets $634M buyout offer — but it’s not from Kindred

July 18, 2014 2:26 pm by | 0 Comments

(Reuters) – Gentiva Health Services Inc rejected Kindred Healthcare Inc’s offer to buy a stake in the home healthcare services provider in favor of a $634.2 million buyout offer from…


Pfizer in-licenses BCRP assay for preclinical drug development

Pfizer in-licenses BCRP assay for preclinical drug development

July 16, 2014 10:00 am by | 0 Comments

US-based Absorption Systems, focusing on novel test systems for drug transporters, said it had inked a licence agreement with US Pfizer Inc (NYSE:PFE), under which Pfizer will in- license its…


Abbott divests non-U.S. generics for developed markets to Mylan

Abbott divests non-U.S. generics for developed markets to Mylan

July 15, 2014 12:27 pm by | 0 Comments

US healthcare company Abbott Laboratories (NYSE:ABT) said yesterday that it would sell its developed markets generics pharmaceuticals operations to local sector player Mylan Inc (NASDAQ:MYL) in an all-stock deal worth…


Google gains some medical cred in deal with Novartis for glucose-sensing contacts

Google gains some medical cred in deal with Novartis for glucose-sensing contacts

July 15, 2014 8:19 am by | 0 Comments

ZURICH (Reuters) – Swiss drugmaker Novartis has struck an agreement with Google to develop “smart” contact lenses that would help diabetics track their blood glucose levels or restore the eye’s…


In hot pursuit of home healthcare services, Kindred sweetens its bid for stake in Gentiva

In hot pursuit of home healthcare services, Kindred sweetens its bid for stake in Gentiva

July 14, 2014 4:10 pm by | 0 Comments

(Reuters) – Kindred Healthcare Inc raised its hostile bid for a stake in Gentiva Health Services Inc, stepping up its pursuit of the home healthcare services provided by Gentiva to…



Neurelis free to develop epilepsy drug after Biotie Therapies declines acquisition

Neurelis free to develop epilepsy drug after Biotie Therapies declines acquisition

July 14, 2014 10:21 am by | 0 Comments

Neurelis Inc, a privately-held San Diego-based specialty pharmaceutical company, has signed a contract with Biotie Therapies Corp, a specialised drug development company, it was revealed on Friday. The contract has…


Shire confirms talks with AbbVie on takeover bid

Shire confirms talks with AbbVie on takeover bid

July 11, 2014 6:52 pm by | 0 Comments

(Reuters) – Shire Plc on Friday confirmed it has held a meeting with U.S. drugmaker AbbVie Inc to discuss AbbVie’s takeover bid for the Dublin-based maker of drugs for rare…


Stryker deals Bone Morphogenetic Protein- 7 assets to Mariel for osteoarthritis treatments

Stryker deals Bone Morphogenetic Protein- 7 assets to Mariel for osteoarthritis treatments

July 8, 2014 10:39 am by | 0 Comments

Mariel Therapeutics Inc., a clinical stage biopharmaceutical company, announced yesterday that it has signed a definitive agreement to acquire Stryker Corporation’s (NYSE: SYK) Bone Morphogenetic Protein-7 (BMP-7) assets. The assets…


Quintiles completes health analytics company Encore Health Resources acquisition

Quintiles completes health analytics company Encore Health Resources acquisition

July 3, 2014 11:20 am by | 0 Comments

Quintiles, a United States-based biopharmaceutical development and commercial outsourcing services company, has acquired Encore Health Resources, a provider of health-information analytics and technology consulting services, it was reported yesterday. The…


AbbVie not giving up on pursuit of Shire, as CEO meets with shareholders in London

AbbVie not giving up on pursuit of Shire, as CEO meets with shareholders in London

July 3, 2014 10:09 am by | 0 Comments

LONDON (Reuters) – AbbVie (ABBV) Chief Executive Richard Gonzalez has pressed the case for his $46 billion pursuit of drugmaker Shire (SHP) in discreet meetings with shareholders in London this…


Amgen, Bind Therapeutics cut ties after cancer drug failure

Amgen, Bind Therapeutics cut ties after cancer drug failure

July 3, 2014 8:07 am by | 0 Comments

(Reuters) – Drug developer Bind Therapeutics said it ended a partnership with Amgen Inc to develop targeted cancer therapy due to unsatisfactory results. Bind’s shares fell 15 percent to $10.95…


Here are 6 trends that will increase healthcare M&A deals in 2014

Here are 6 trends that will increase healthcare M&A deals in 2014

July 2, 2014 5:31 pm by | 0 Comments

A survey of healthcare and life science professionals and investors suggests healthcare M&A activity will surge past 2013 levels when there were 394 deals valued at $97 billion. The report…


RedHill Biopharma, WILEX sign license deal for cancer drug Mesupron

RedHill Biopharma, WILEX sign license deal for cancer drug Mesupron

July 2, 2014 2:00 pm by | 0 Comments

RedHill Biopharma, an Israel-based biopharmaceutical company, has signed an exclusive license agreement with Germany-based WILEX, it was revealed yesterday. The contract has been signed for the oncology drug candidate, Mesupron,…